All Stories

  1. Characterising airway inflammation in Aboriginal and Torres Strait Islander and non-Aboriginal and Torres Strait Islander adults with asthma and COPD
  2. Immune checkpoints are suppressed during pregnancy following influenza A virus infection
  3. Bile acids in the lower airways is associated with airway microbiota changes in chronic obstructive pulmonary disease: an observational study
  4. Allergic broncho‐pulmonary aspergillosis: Old disease, new frontiers
  5. Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study
  6. Endoplasmic reticulum stress enhances the expression of TLR3-induced TSLP by airway epithelium
  7. Mapping the Common Barriers to Optimal COPD Care in High and Middle-Income Countries: Qualitative Perspectives from Clinicians
  8. Biologic therapies for severe asthma with persistent type 2 inflammation
  9. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  10. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  11. Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study
  12. Mapping the common barriers to optimal COPD care in high and middle-income countries: qualitative perspectives from clinicians
  13. Inflammatory and antiviral responses to influenza A virus infection are dysregulated in pregnant mice with allergic airway disease
  14. Upper Respiratory Tract OC43 Infection Model for Investigating Airway Immune-modifying Therapies
  15. Mechanical forces suppress antiviral innate immune responses from asthmatic airway epithelial cells following rhinovirus infection
  16. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
  17. Saline at lower tonicity in CF (SALTI-CF) trial comparing 0.9% v 3% v 6% nebulised saline
  18. BILE ACIDS IN LOWER AIRWAYS AS A NOVEL INDICATOR OF AIRWAY MICROBIOTA CHANGES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
  19. Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19
  20. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics
  21. Comparison of commercially available differentiation media on morphology, function, and virus-host interaction in conditionally reprogrammed human bronchial epithelial cells
  22. A systematic review of the colorectal microbiome in adult cystic fibrosis patients
  23. Probiotic Bifidobacterium longum subsp. longum Protects against Cigarette Smoke-Induced Inflammation in Mice
  24. Survival of people with cystic fibrosis in Australia
  25. Conditionally reprogrammed asthmatic bronchial epithelial cells express lower FOXJ1 at terminal differentiation and lower IFNs following RV-A1 infection
  26. Obesity and COVID-19 Disease: To Inflame or Not
  27. Association between dietary fibre, microbial metabolites and airway obstruction in COPD patients and murine models
  28. Crucial role of iron metabolism in determining outcomes of influenza A virus infection and disease
  29. Histone deacetylase-6 (HDAC6) promotes protective responses during murine influenza A virus (IAV) infection
  30. Hydrogen sulfide attenuates cigarette smoke-induced oxidative stress and inflammation in human primary bronchial epithelial cells and experimental COPD
  31. Relationship between interleukin-13 and transferrin receptor-1 responses in the pathogenesis of asthma
  32. Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis
  33. We need to understand why viral infections lead to acute asthma
  34. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
  35. IL-25 blockade augments antiviral immunity during respiratory virus infection
  36. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network FluCAN
  37. Mental health care needs in cystic fibrosis: A scoping review
  38. Understanding motivation for Australian adolescents and young adults with cystic fibrosis: Modifiable factors to support self‐management
  39. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities
  40. Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)
  41. Factors Associated with Asthma Exacerbations During Pregnancy
  42. Increased cough, mucus and wheeze characterise COPD and Asthma in Australian Aboriginal adults
  43. We are not doing enough to prevent the spread of COVID‐19 and other respiratory viruses in Australian hospitals
  44. Transcriptomics of biopsies identifies novel genes and pathways linked to neutrophilic inflammation in severe asthma
  45. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights
  46. Dysregulated actin cytoskeleton associated with barrier dysfunction in asthma
  47. Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
  48. Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration
  49. Asthma-COPD overlap: current understanding and the utility of experimental models
  50. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma
  51. Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections
  52. Hemopexin: A Novel Anti-inflammatory Marker for Distinguishing COPD From Asthma
  53. TLR2-mediated innate immune priming boosts lung anti-viral immunity
  54. Molecular and Immunological Mechanisms Underlying the Various Pharmacological Properties of the Potent Bioflavonoid, Rutin
  55. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells
  56. Curcumin-loaded niosomes downregulate mRNA expression of pro-inflammatory markers involved in asthma: an in vitro study
  57. Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization
  58. Australian cystic fibrosis community views on organoids
  59. PAT in the ER for Transmembrane Protein Folding
  60. Severe Nocardia pneumonia in an immunocompromised patient with alpha‐1 antitrypsin deficiency
  61. Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation
  62. Managing T2-High Inflammation in Severe Asthma - Are Biomarkers Better Than Clinician Judgement?
  63. Late Breaking Abstract - ACE2 expression in lower airway epithelial cells is increased with age and in males, but is less in asthma
  64. ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma
  65. A Sputum 6 Gene Expression Signature Predicts Inflammatory Phenotypes and Future Exacerbations of COPD
  66. Molecular mechanisms of action of naringenin in chronic airway diseases
  67. Celastrol-loaded liquid crystalline nanoparticles as an anti-inflammatory intervention for the treatment of asthma
  68. Asthma and the Dysregulated Immune Response to Rhinovirus
  69. Management of acute COPD exacerbations in Australia: do we follow the guidelines?
  70. A survey of specialist opinions on biomarker use in severe asthma in Australia: scepticism but hope?
  71. Contemporary Concise Review 2019: Asthma
  72. Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*
  73. Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases
  74. Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma
  75. Sputum transcriptomics implicates increased p38 signalling activity in severe asthma
  76. Targeting treatable traits in severe asthma: a randomised controlled trial
  77. Antiviral immunity is impaired in COPD patients with frequent exacerbations
  78. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease
  79. Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma
  80. Nasal epithelial cells to assess in vitro immune responses to respiratory virus infection in pregnant women with asthma
  81. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
  82. Blood Neutrophils In COPD But Not Asthma Exhibit A Primed Phenotype With Downregulated CD62L Expression
  83. Hypoxia‐inducible factor and bacterial infections in chronic obstructive pulmonary disease
  84. People with asthma are more likely to become ill from influenza
  85. A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
  86. Asthmatic airway epithelial cells subjected to apical mechanical stress exhibit suppressed interferon release following viral infection
  87. Circulatory neutrophils in COPD feature downregulated CD62L expression in comparison with asthma and healthy participants
  88. Inhibition of ER stress suppresses IL-13 induced airway epithelial remodeling
  89. Endobronchial biopsy gene expression between different severe asthma inflammatory phenotypes
  90. Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses
  91. Sputum gene signature comparison study between U-BIOPRED and Australia asthma cohorts
  92. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)
  93. Fibulin-1c regulates transforming growth factor–β activation in pulmonary tissue fibrosis
  94. RIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses
  95. Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production
  96. Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
  97. IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis
  98. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome
  99. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report
  100. The importance of acute asthma.
  101. CSF3R/CD114 mediates infection-dependent transition to severe asthma
  102. Hypersegmented airway neutrophils and its association with reduced lung function in adults with obstructive airway disease: an exploratory study
  103. Molecular modulators of celastrol as the keystones for its diverse pharmacological activities
  104. Enhancing tristetraprolin activity reduces the severity of cigarette smoke‐induced experimental chronic obstructive pulmonary disease
  105. The interplay of the host, virus, and the environment
  106. Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma
  107. Multi-Centre Ethics and Research Governance Review Can Impede Non-Interventional Clinical Research
  108. Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease
  109. Nebulised hypertonic saline for cystic fibrosis
  110. Treatable traits can be identified in a severe asthma registry and predict future exacerbations
  111. Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease
  112. Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors
  113. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
  114. Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics
  115. Appropriate use of oral corticosteroids for severe asthma
  116. Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: a systematic literature review and meta-analysis
  117. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations
  118. Trends in asthma self-management skills and inhaled corticosteroid use during pregnancy and postpartum from 2004 to 2017
  119. Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches
  120. Developments in cystic fibrosis personalised epithelial assays: Science and patient perspectives
  121. Pseudomonas pharyngitis in a cystic fibrosis patient
  122. Immunological axis of curcumin-loaded vesicular drug delivery systems
  123. Impaired Th1 responses in patients with acute exacerbations of COPD are improved with PD-1 blockade
  124. Understanding the Unfolded Protein Response in the Pathogenesis of Asthma
  125. Respiratory Viruses and Asthma
  126. Eosinophilia as a treatable trait in three patients with asthma and COPD
  127. Pathophysiology of severe asthma: We’ve only just started
  128. Systematic review and website presentation of validated dietary assessment tools
  129. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c
  130. ENHANCED CD147 EXPRESSION AFTER H1N1 INFECTION; A POTENTIAL MECHANISM FOR AIRWAY EPITHELIUM IMPAIRMENT IN ASTHMA
  131. SPUTUM 6 GENE EXPRESSION SIGNATURE PREDICTS INFLAMMATORY PHENOTYPE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  132. A new website to support dietary assessment in health research: Nutritools.org
  133. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD
  134. Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT)
  135. A transcriptomic comparison between nasal and bronchial airway epithelia from children
  136. Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells
  137. Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma
  138. MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD
  139. Effects of Fruit and Vegetable Consumption on Risk of Asthma, Wheezing and Immune Responses: A Systematic Review and Meta-Analysis
  140. Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling
  141. Role of miR-218 in COPD
  142. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
  143. Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
  144. Severe asthma: Current management, targeted therapies and future directions-A roundtable report
  145. Acute myocardial infarction in disseminated mucormycosis infection
  146. The genetic and epigenetic landscapes of the epithelium in asthma
  147. A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics
  148. Effect of oxidative stress and rhinovirus infection on mitochondrial/endoplasmic reticular function in human primary bronchial epithelial cells
  149. Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease
  150. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive steroid-resistant asthma
  151. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
  152. Recent advances in understanding and managing asthma
  153. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD
  154. Impaired Antiviral Stress Granule and IFN-β Enhanceosome Formation Enhances Susceptibility to Influenza Infection in Chronic Obstructive Pulmonary Disease Epithelium
  155. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion
  156. Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases
  157. Advances in the treatment of virus-induced asthma
  158. Acute oxygen therapy: a review of prescribing and delivery practices
  159. Targeted therapeutics for severe refractory asthma: monoclonal antibodies
  160. Diagnosis and investigation in the severe asthma clinic
  161. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis
  162. Innate Immunity and Immune Evasion by Enterovirus 71
  163. Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014
  164. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease
  165. Can blood eosinophils predict sputum eosinophils in stable COPD?
  166. Potential role of SPARC, a downstream mediator of TGF-b in chronic airways disease
  167. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma
  168. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis
  169. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia
  170. Targeting PI3K-p110α Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease
  171. The Placental Protein Syncytin-1 Impairs Antiviral Responses and Exaggerates Inflammatory Responses to Influenza
  172. CD8 T cells and dendritic cells: key players in the attenuated maternal immune response to influenza infection
  173. World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance
  174. Airwayβ-Defensin-1 Protein Is Elevated in COPD and Severe Asthma
  175. 81
  176. 82
  177. 175
  178. 147
  179. Differential injurious effects of ambient and traffic-derived particulate matter on airway epithelial cells
  180. How the placenta makes pregnant women vulnerable to influenza (Flu)
  181. PP38 Development of a new UK food composition database
  182. The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
  183. Cough Formation in Viral Infections in Children
  184. The interaction between mother and fetus and the development of allergic asthma
  185. TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection.
  186. A Prospective Study of Respiratory Viral Infection in Pregnant Women With and Without Asthma
  187. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission
  188. Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010–11 Seasons: A Test-negative Observational Study
  189. Plasmacytoid Dendritic Cells and CD8 T Cells From Pregnant Women Show Altered Phenotype and Function Following H1N1/09 Infection
  190. Alterations in inflammatory, antiviral and regulatory cytokine responses in peripheral blood mononuclear cells from pregnant women with asthma
  191. Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease
  192. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis
  193. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity
  194. Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD
  195. Deficient antiviral responses to influenza in primary bronchial epithelial cells of chronic obstructive pulmonary disease
  196. Innate immunity to influenza in chronic airways diseases
  197. RAGE: a new frontier in chronic airways disease
  198. SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres
  199. Viral infections trigger exacerbations of cystic fibrosis in adults and children: Figure 1–
  200. Pregnant Women Have Attenuated Innate Interferon Responses to 2009 Pandemic Influenza A Virus Subtype H1N1
  201. Characteristics of a Widespread Community Cluster of H275Y Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Australia
  202. Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines
  203. Airway inflammation in asthma, a single measurement is not enough
  204. Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPD
  205. Critical Role of Constitutive Type I Interferon Response in Bronchial Epithelial Cell to Influenza Infection
  206. Serum amyloid A opposes lipoxin A 4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease
  207. Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection
  208. Developments in the field of allergy in 2010 through the eyes of Clinical and Experimental Allergy
  209. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study
  210. Soluble RAGE is deficient in neutrophilic asthma and COPD
  211. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma
  212. P2-316 Adult height in relation to cancer mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
  213. Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD
  214. Human Influenza Is More Effective than Avian Influenza at Antiviral Suppression in Airway Cells
  215. A Novel E3 Ubiquitin Ligase Links Rhinovirus Infection To Exacerbation Of Asthma
  216. Respiratory Examination
  217. Characterization of innate immune signalling receptors in virus-induced acute asthma
  218. Antioxidant and Anti-Inflammatory Effects of Resveratrol in Airway Disease
  219. Down-titration from high-dose combination therapy in asthma: Removal of long-acting β2-agonist
  220. Viral and bacterial interactions in pneumonia
  221. TLR5 is not required for flagellin-mediated exacerbation of DSS colitis
  222. Asthma during pregnancy alters immune cell profile and airway epithelial chemokine release
  223. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide
  224. Nebulised hypertonic saline for cystic fibrosis
  225. Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients
  226. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains
  227. Pathogenesis of ABPA
  228. Guest Editorial
  229. Innate immune response to viral infection of the lungs
  230. Flagellin exacerbates DSS induced Colitis via TLR5 independent mechanisms
  231. SUPPLEMENTATION OF LONG CHAIN N-3 POLYUNSATURATED FATTY ACIDS INCREASES THE UTILIZATION OF LYCOPENE IN CULTURED AIRWAY EPITHELIAL CELLS
  232. Anti-inflammatory effects of long-chain n-3 PUFA in rhinovirus-infected cultured airway epithelial cells
  233. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii
  234. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages
  235. The role of exhaled nitric oxide and exhaled breath condensates in evaluating airway inflammation in asthma
  236. Understanding the mechanisms of viral induced asthma: New therapeutic directions
  237. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease
  238. IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations
  239. Asthma exacerbations {middle dot} 3: Pathogenesis
  240. Role of deficient type III interferon-λ production in asthma exacerbations
  241. Nebulised hypertonic saline for cystic fibrosis
  242. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus
  243. Induced Sputum 8-Isoprostane Concentrations in Inflammatory Airway Diseases
  244. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment
  245. Hyperkalaemic ascending paralysis
  246. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial
  247. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques
  248. Airway inflammation in thunderstorm asthma
  249. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma
  250. Optimization of sputum-processing methods for the measurement of interleukin-5: Effects of protease inhibition
  251. Non-invasive ventilation in acute respiratory failure
  252. Safety of sputum induction with isotonic saline in adults with acute severe asthma
  253. Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment
  254. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma
  255. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis
  256. Induced sputum eosinophils in the assessment of asthma and chronic cough*
  257. Bronchitis
  258. Difficult Asthma
  259. Non-Invasive Ventilation in Acute Respiratory Failure